10-Q/A Filing

ACCELERATE DIAGNOSTICS, INC CIK: 727207 Q3 2012

Filing Information

Form Type	10-Q/A
Accession Number	`0001000096-12-000109`
Period End Date	20120430
Filing Date	20120615
Fiscal Year	2012
Fiscal Period	Q3
XBRL Instance	axk-20120430.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 56 Income Statement 76 Cash Flow Statement 50

Balance Sheet 56 line items

Line Item	Tag	Value	Unit	Period
Common Stock, no par value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock, no par value	`CommonStockParOrStatedValuePerShare`	-	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	19.00M	shares	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	19.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$213.00K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	11.10M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	11.10M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$372.26K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	11.10M	shares	Point-in-time
Trade Accounts receivable	`ReceivablesNetCurrent`	$596.13K	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	11.10M	shares	Point-in-time
Trade Accounts receivable	`ReceivablesNetCurrent`	$600.00K	USD	Point-in-time
Shares held for employee benefit	`DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital`	$1.13M	USD	Point-in-time
Shares held for employee benefit	`DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital`	$1.13M	USD	Point-in-time
Inventory	`InventoryNet`	$30.28K	USD	Point-in-time
Inventory	`InventoryNet`	$30.28K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$24.78K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$20.58K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$868.05K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.42M	USD	Point-in-time
Long Term Accounts Receivable, Net of current portion	`LongTermInvestmentsAndReceivablesNet`	$745.44K	USD	Point-in-time
Long Term Accounts Receivable, Net of current portion	`LongTermInvestmentsAndReceivablesNet`	$743.40K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.98K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$3.53K	USD	Point-in-time
Investments, net	`Goodwill`	$1.30M	USD	Point-in-time
Investments, net	`Goodwill`	$1.41M	USD	Point-in-time
Intellectual property, net	`FiniteLivedIntangibleAssetsNet`	$2.79M	USD	Point-in-time
Intellectual property, net	`FiniteLivedIntangibleAssetsNet`	$2.65M	USD	Point-in-time
Total assets	`Assets`	$6.26M	USD	Point-in-time
Total assets	`Assets`	$5.68M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$49.98K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$34.96K	USD	Point-in-time
Accrued compensation and other liabilities	`EmployeeRelatedLiabilitiesCurrent`	$43.85K	USD	Point-in-time
Accrued compensation and other liabilities	`EmployeeRelatedLiabilitiesCurrent`	$24.58K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$93.45K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$9.80K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$69.34K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$187.29K	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$1.47M	USD	Point-in-time
Deferred compensation	`DeferredCompensationLiabilityCurrent`	$1.38M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.45M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.66M	USD	Point-in-time
Common Stock, no par value; 19,000,000 shares authorized; 11,103,367 shares issued and outstanding	`CommonStockNoParValue`	$14.33M	USD	Point-in-time
Common Stock, no par value; 19,000,000 shares authorized; 11,103,367 shares issued and outstanding	`CommonStockNoParValue`	$14.33M	USD	Point-in-time
Contributed capital	`AdditionalPaidInCapitalCommonStock`	$1.59M	USD	Point-in-time
Contributed capital	`AdditionalPaidInCapitalCommonStock`	$1.25M	USD	Point-in-time
Accumulated (deficit)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-10.49M	USD	Point-in-time
Accumulated (deficit)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-11.63M	USD	Point-in-time
Shares held for employee benefit (1,129,110 shares at cost)	`SharesHeldInEmployeeStockOptionPlanAllocated`	-273,600.00	shares	Point-in-time
Shares held for employee benefit (1,129,110 shares at cost)	`SharesHeldInEmployeeStockOptionPlanAllocated`	-273,600.00	shares	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$4.82M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$4.02M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$6.26M	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$5.68M	USD	Point-in-time

Income Statement 76 line items

Line Item	Tag	Value	Unit	Period
OptiChem(R) revenues	`LicensesRevenue`	$40.81K	USD	3 Qtrs
OptiChem(R) revenues	`LicensesRevenue`	$25.77K	USD	1 Quarter
OptiChem(R) revenues	`LicensesRevenue`	$13.21K	USD	1 Quarter
OptiChem(R) revenues	`LicensesRevenue`	$33.54K	USD	3 Qtrs
Technical development fees	`ProfessionalAndContractServicesExpense`	$-214.50K	USD	1 Quarter
Technical development fees	`ProfessionalAndContractServicesExpense`	-	USD	1 Quarter
Technical development fees	`ProfessionalAndContractServicesExpense`	$-734.91K	USD	3 Qtrs
Technical development fees	`ProfessionalAndContractServicesExpense`	$-140.00K	USD	3 Qtrs
Qualified Therapeutic Discovery Grant	`RevenueFromGrants`	-	USD	1 Quarter
Qualified Therapeutic Discovery Grant	`RevenueFromGrants`	$244.48K	USD	3 Qtrs
Qualified Therapeutic Discovery Grant	`RevenueFromGrants`	-	USD	3 Qtrs
Qualified Therapeutic Discovery Grant	`RevenueFromGrants`	-	USD	1 Quarter
License Fee	`CostOfServicesLicensesAndServices`	-	USD	1 Quarter
License Fee	`CostOfServicesLicensesAndServices`	$-50.00K	USD	3 Qtrs
License Fee	`CostOfServicesLicensesAndServices`	-	USD	1 Quarter
License Fee	`CostOfServicesLicensesAndServices`	-	USD	3 Qtrs
Total Revenues	`SalesRevenueNet`	$1.02M	USD	3 Qtrs
Total Revenues	`SalesRevenueNet`	$13.21K	USD	1 Quarter
Total Revenues	`SalesRevenueNet`	$223.54K	USD	3 Qtrs
Total Revenues	`SalesRevenueNet`	$240.27K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$126.92K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$345.60K	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$302.90K	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$109.86K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$905.45K	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$606.69K	USD	3 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$248.21K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$181.88K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$64.50K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$63.46K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$189.86K	USD	3 Qtrs
Amortization	`AmortizationOfIntangibleAssets`	$192.84K	USD	3 Qtrs
Marketing and sales	`SellingAndMarketingExpense`	$7.74K	USD	3 Qtrs
Marketing and sales	`SellingAndMarketingExpense`	$4.56K	USD	3 Qtrs
Marketing and sales	`SellingAndMarketingExpense`	$1.25K	USD	1 Quarter
Marketing and sales	`SellingAndMarketingExpense`	$344.00	USD	1 Quarter
Depreciation	`DepreciationDepletionAndAmortization`	$516.00	USD	1 Quarter
Depreciation	`DepreciationDepletionAndAmortization`	$599.00	USD	1 Quarter
Depreciation	`DepreciationDepletionAndAmortization`	$1.80K	USD	3 Qtrs
Depreciation	`DepreciationDepletionAndAmortization`	$1.55K	USD	3 Qtrs
Total costs and expenses	`CostsAndExpenses`	$1.41M	USD	3 Qtrs
Total costs and expenses	`CostsAndExpenses`	$423.42K	USD	1 Quarter
Total costs and expenses	`CostsAndExpenses`	$1.15M	USD	3 Qtrs
Total costs and expenses	`CostsAndExpenses`	$374.11K	USD	1 Quarter
(Loss) from operations	`OperatingIncomeLoss`	$-131.49K	USD	3 Qtrs
(Loss) from operations	`OperatingIncomeLoss`	$-133.84K	USD	1 Quarter
(Loss) from operations	`OperatingIncomeLoss`	$-1.18M	USD	3 Qtrs
(Loss) from operations	`OperatingIncomeLoss`	$-410.22K	USD	1 Quarter
Interest and dividend income	`OtherNonoperatingIncome`	$11.90K	USD	3 Qtrs
Interest and dividend income	`OtherNonoperatingIncome`	$11.48K	USD	3 Qtrs
Interest and dividend income	`OtherNonoperatingIncome`	$4.08K	USD	1 Quarter
Interest and dividend income	`OtherNonoperatingIncome`	$4.06K	USD	1 Quarter
Unrealized gain on investments	`UnrealizedGainLossOnInvestments`	$17.77K	USD	1 Quarter
Unrealized gain on investments	`UnrealizedGainLossOnInvestments`	$5.76K	USD	1 Quarter
Unrealized gain on investments	`UnrealizedGainLossOnInvestments`	$29.02K	USD	3 Qtrs
Unrealized gain on investments	`UnrealizedGainLossOnInvestments`	$36.91K	USD	3 Qtrs
Gain on the sale of assets	`GainsLossesOnSalesOfAssets`	$1.00K	USD	3 Qtrs
Gain on the sale of assets	`GainsLossesOnSalesOfAssets`	-	USD	1 Quarter
Gain on the sale of assets	`GainsLossesOnSalesOfAssets`	-	USD	3 Qtrs
Gain on the sale of assets	`GainsLossesOnSalesOfAssets`	-	USD	1 Quarter
Total other income	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$48.39K	USD	3 Qtrs
Total other income	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$21.83K	USD	1 Quarter
Total other income	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$41.91K	USD	3 Qtrs
Total other income	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$9.84K	USD	1 Quarter
Net (loss)	`NetIncomeLoss`	$-83.10K	USD	3 Qtrs
Net (loss)	`NetIncomeLoss`	$-388.38K	USD	1 Quarter
Net (loss)	`NetIncomeLoss`	$-123.99K	USD	1 Quarter
Net (loss)	`NetIncomeLoss`	$-1.14M	USD	3 Qtrs
Basic and diluted net loss per share	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	1 Quarter
Basic and diluted net loss per share	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
Basic and diluted net loss per share	`EarningsPerShareBasicAndDiluted`	$-0.10	USD	3 Qtrs
Basic and diluted net loss per share	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	3 Qtrs
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	10.70M	shares	1 Quarter
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	11.10M	shares	1 Quarter
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	10.70M	shares	3 Qtrs
Weighted average shares outstanding	`WeightedAverageNumberOfSharesOutstandingBasic`	11.10M	shares	3 Qtrs

Cash Flow Statement 50 line items

Line Item	Tag	Value	Unit	Period
Net Income (loss)	`NetIncomeLoss`	$-83.10K	USD	3 Qtrs
Net Income (loss)	`NetIncomeLoss`	$-388.38K	USD	1 Quarter
Net Income (loss)	`NetIncomeLoss`	$-123.99K	USD	1 Quarter
Net Income (loss)	`NetIncomeLoss`	$-1.14M	USD	3 Qtrs
Depreciation	`Depreciation`	$1.80K	USD	3 Qtrs
Depreciation	`Depreciation`	$1.55K	USD	3 Qtrs
Amortization	`AmortizationOfIntangibleAssets`	$64.50K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$63.46K	USD	1 Quarter
Amortization	`AmortizationOfIntangibleAssets`	$189.86K	USD	3 Qtrs
Amortization	`AmortizationOfIntangibleAssets`	$192.84K	USD	3 Qtrs
Fair value of stock options granted for services	`ShareBasedCompensation`	$347.61K	USD	3 Qtrs
Fair value of stock options granted for services	`ShareBasedCompensation`	$18.68K	USD	3 Qtrs
Unrealized holding (gain) loss on investments	`GainLossOnInvestments`	$-36.91K	USD	3 Qtrs
Unrealized holding (gain) loss on investments	`GainLossOnInvestments`	$-29.02K	USD	3 Qtrs
Reinvested earnings-interest and dividends	`OtherNoncashExpense`	$-5.72K	USD	3 Qtrs
Reinvested earnings-interest and dividends	`OtherNoncashExpense`	$-4.38K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-18.64K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-1.83K	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	-	USD	3 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$2.07K	USD	3 Qtrs
Prepaid expense and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-12.77K	USD	3 Qtrs
Prepaid expense and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-4.20K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$15.03K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$62.65K	USD	3 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$14.49K	USD	3 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$19.27K	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$83.66K	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-20.23K	USD	3 Qtrs
Deferred compensation	`DeferredCompensationArrangementWithIndividualCompensationExpense`	$97.54K	USD	3 Qtrs
Deferred compensation	`DeferredCompensationArrangementWithIndividualCompensationExpense`	$90.99K	USD	3 Qtrs
Net cash provided (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-431.67K	USD	3 Qtrs
Net cash provided (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$211.06K	USD	3 Qtrs
Sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Sale of common stock	`ProceedsFromIssuanceOfCommonStock`	-	USD	3 Qtrs
Purchases of equipment and patents	`PaymentsToAcquirePropertyPlantAndEquipment`	$56.20K	USD	3 Qtrs
Purchases of equipment and patents	`PaymentsToAcquirePropertyPlantAndEquipment`	$47.07K	USD	3 Qtrs
Contribution to deferred compensation trust	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition`	$-75.00K	USD	3 Qtrs
Contribution to deferred compensation trust	`AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition`	$-75.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-122.07K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-131.20K	USD	3 Qtrs
Increase (Decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$88.99K	USD	3 Qtrs
Increase (Decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-562.86K	USD	3 Qtrs
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$213.00K	USD	Point-in-time
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Beginning balance	`CashAndCashEquivalentsAtCarryingValue`	$372.26K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$775.86K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$213.00K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$283.27K	USD	Point-in-time
Ending balance	`CashAndCashEquivalentsAtCarryingValue`	$372.26K	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.